Cellectis
Company developing genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy.
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).
Visit website: https://www.cellectis.com/
Details last updated 27-Feb-2021
Cellectis News
10 Hot European Biotechs to watch in 2016
Labiotech - 12-Jan-2016
Including immuno-oncology treatments, antibody delivery, Tau-aggregation inhibitors and mRNA ther...
Read more...